课题基金 / 基金详情

Targeting the Exercise-Inducible Signalling Factor FGF21 as a Novel Approach to Mitigate the Side Effects of Antipsychotics

Targeting the Exercise-Inducible Signalling Factor FGF21 as a Novel Approach to Mitigate the Side Effects of Antipsychotics
靶向运动诱导信号因子 FGF21 作为减轻抗精神病药物副作用的新方法
批准号:
487505
负责人:
Wright David
金额:
$69.66万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2023
资助国家:
加拿大
项目状态:
未结题
起止时间:
2023-09-01 至 2028-09-01

项目摘要

项目成果

Wright David的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Antipsychotic medications (AP) are used for treating schizophrenia. While effective they have harmful side effects such as causing weight gain and impairing how the body uses fat and sugar. The use of APs increases the risk of developing diabetes and card
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying a Novel Role for GDF15 during Exercise
  • 批准号:
    443748
  • 项目类别:
    Operating Grants
  • 资助金额:
    $47.65万
  • 财政年份:
    2021
  • 负责人:
    Wright David
  • 依托单位:
Targeting Exercise Activated Pathways to Counter the Side Effects of Antipsychotic Drugs
  • 批准号:
    379639
  • 项目类别:
    Operating Grants
  • 资助金额:
    $41.8万
  • 财政年份:
    2018
  • 负责人:
    Wright David
  • 依托单位:
Saltin International PhD Course in Clinical and Exercise Physiology
  • 批准号:
    365637
  • 项目类别:
    Miscellaneous Programs
  • 资助金额:
    $1.46万
  • 财政年份:
    2017
  • 负责人:
    Wright David
  • 依托单位:
In search of a nursing standpoint: Investigating nurses' values regarding assisted death
  • 批准号:
    348187
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2016
  • 负责人:
    Wright David
  • 依托单位:
海外基金